Rankings
▼
Calendar
TNGX FY 2019 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$25M
Gross Profit
-$8M
-30.9% margin
Operating Income
-$15M
-61.5% margin
Net Income
-$14M
-57.2% margin
EPS (Diluted)
$-1.57
Cash Flow
Operating Cash Flow
-$25M
Free Cash Flow
-$27M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$56M
Total Liabilities
$48M
Stockholders' Equity
$8M
Cash & Equivalents
$23M
← Q1 2020
All Quarters